Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive, human epidermal growth factor receptor 2-positive breast cancer cells

The Janus kinase (JAK)1 and JAK2 inhibitor, ruxolitinib, and the active form of vitamin D (calcitriol) were previously reported to possess anticancer effects in breast cancer. The present study investigated the combined effects of ruxolitinib and calcitriol on an estrogen receptor (ER)-positive, hum...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Seung Taek, Jeon, Ye Won, Gwak, Hongki, Kim, Se Young, Suh, Young Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865997/
https://www.ncbi.nlm.nih.gov/pubmed/29436642
http://dx.doi.org/10.3892/mmr.2018.8580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865997/
https://www.ncbi.nlm.nih.gov/pubmed/29436642
http://dx.doi.org/10.3892/mmr.2018.8580

Ejemplares similares